ArticleInternational cancer conference journal2026
Three cases of esophagorespiratory fistula following neoadjuvant DCF therapy for resectable esophageal cancer.
Article in International cancer conference journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemotherapy with 5-FU, cisplatin, and docetaxel (DCF) is standard for resectable esophageal cancer in Japan but is linked to severe adverse events. We report three cases of esophagorespiratory fistulas (ERFs) occurring during DCF therapy. Case 1: A 72-year-old woman (cStage II) developed fever after two DCF cycles. CT and esophagography confirmed an ERF. An esophageal stent was placed, but she later opted for best supportive care. Case 2: A 53-year-old man (cStage IIIB) developed pneumatosis intestinalis and pneumonia nine days into DCF. Imaging confirmed an ERF. He received a stent on day 19 and continued chemotherapy for over a year. Case 3: A 65-year-old man (cStage IIIA) presented with dyspnea eight days after starting DCF. CT revealed pneumothorax and pyothorax. A stent was placed on day 19. His condition initially improved but later declined, leading to best supportive care. DCF therapy may enhance survival but carries significant risk for ERFs. Early recognition of symptoms and rapid intervention are critical to managing complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.